Traumatic brain injury (TBI) is followed by a state of metabolic dysfunction, affecting the ability of neurons to use energy and support brain plasticity; there is no effective
therapy to counteract the TBI pathology.
Brain-derived neurotrophic factor (
BDNF) has an exceptional capacity to support metabolism and plasticity, which highly contrasts with its poor pharmacological profile. We evaluated the action of a
flavonoid derivative
7,8-dihydroxyflavone (7,8-DHF), a
BDNF receptor (TrkB) agonist with the pharmacological profile congruent for potential human
therapies. Treatment with 7,8-DHF (5mg/kg, ip, daily for 7 days) was effective to ameliorate the effects of TBI on plasticity markers (CREB phosphorylation, GAP-43 and
syntaxin-3 levels) and memory function in Barnes maze test. Treatment with 7,8-DHF restored the decrease in
protein and phenotypic expression of TrkB phosphorylation after TBI. In turn, intrahippocampal
injections of
K252a, a TrkB antagonist, counteracted the 7,8-DHF induced TrkB signaling activation and memory improvement in TBI, suggesting the pivotal role of TrkB signaling in cognitive performance after
brain injury. A potential action of 7,8-DHF on cell energy homeostasis was corroborated by the normalization in levels of PGC-1α, TFAM, COII, AMPK and
SIRT1 in animals subjected to TBI. Results suggest a potential mechanism by which 7,8-DHF counteracts TBI pathology via activation of the
TrkB receptor and engaging the interplay between cell energy management and synaptic plasticity. Since metabolic dysfunction is an important risk factor for the development of neurological and
psychiatric disorders, these results set a precedent for the
therapeutic use of 7,8-DHF in a larger context.